https://www.bloomberg.com/news/articles/2024-06-20/gilead-shot-prevents-100-of-hiv-cases-in-trial-of-african-women

Skip to content
Bloomberg the Company & Its ProductsThe Company & its Products
Bloomberg Terminal Demo RequestBloomberg Anywhere Remote Login
Bloomberg Anywhere LoginBloomberg Customer SupportCustomer Support

  * Bloomberg

    Connecting decision makers to a dynamic network of information,
    people and ideas, Bloomberg quickly and accurately delivers
    business and financial information, news and insight around the
    world

    For Customers

      + Bloomberg Anywhere Remote Login
      + Software Updates
      + Manage Products and Account Information

    Support

    Americas+1 212 318 2000

    EMEA+44 20 7330 7500

    Asia Pacific+65 6212 1000

  * Company

      + About
      + Careers
      + Diversity and Inclusion
      + Tech At Bloomberg
      + Philanthropy
      + Sustainability
      + Bloomberg London
      + Bloomberg Beta
      + Gender-Equality Index

    Communications

      + Press Announcements
      + Press Contacts

    Follow

      + Facebook
      + Instagram
      + LinkedIn
      + Twitter
      + YouTube
  * Products

      + Bloomberg Terminal
      + Data
      + Trading
      + Risk
      + Compliance
      + Indices

    Industry Products

      + Bloomberg Law
      + Bloomberg Tax
      + Bloomberg Government
      + BloombergNEF
  * Media

      + Bloomberg Markets
      + Bloomberg Technology
      + Bloomberg Pursuits
      + Bloomberg Politics
      + Bloomberg Opinion
      + Bloomberg Businessweek
      + Bloomberg Live Conferences
      + Bloomberg Radio
      + Bloomberg Television
      + News Bureaus

    Media Services

      + Bloomberg Media Distribution
      + Advertising

  * Company

      + About
      + Careers
      + Diversity and Inclusion
      + Tech At Bloomberg
      + Philanthropy
      + Sustainability
      + Bloomberg London
      + Bloomberg Beta
      + Gender-Equality Index

    Communications

      + Press Announcements
      + Press Contacts

    Follow

      + Facebook
      + Instagram
      + LinkedIn
      + Twitter
      + YouTube
  * Products

      + Bloomberg Terminal
      + Data
      + Trading
      + Risk
      + Compliance
      + Indices

    Industry Products

      + Bloomberg Law
      + Bloomberg Tax
      + Bloomberg Government
      + Bloomberg Environment
      + BloombergNEF
  * Media

      + Bloomberg Markets
      + Bloomberg
        Technology
      + Bloomberg Pursuits
      + Bloomberg Politics
      + Bloomberg Opinion
      + Bloomberg
        Businessweek
      + Bloomberg Live Conferences
      + Bloomberg Radio
      + Bloomberg Television
      + News Bureaus

    Media Services

      + Bloomberg Media Distribution
      + Advertising
  * Bloomberg

    Connecting decision makers to a dynamic network of information,
    people and ideas, Bloomberg quickly and accurately delivers
    business and financial information, news and insight around the
    world

    For Customers

      + Bloomberg Anywhere Remote Login
      + Software Updates
      + Manage Contracts and Orders

    Support

    Americas+1 212 318 2000

    EMEA+44 20 7330 7500

    Asia Pacific+65 6212 1000

 
Sign InSubscribe
Live TV
Markets
Economics
Industries
Tech
Politics
Businessweek
Opinion
More
US Edition
 
Subscribe
Industries
Health

Gilead Shot Prevents All HIV Cases in Trial of African Women

  * First big trial to reduce HIV infections to zero, Gilead says
  * Shares of drugmaker jump the most in over a year and a half

Gilead Sciences headquarters in Foster City, California.

Gilead Sciences headquarters in Foster City, California.

Photographer: David Paul Morris/Bloomberg
Gift this article
 
Have a confidential tip for our reporters? Get in Touch
 
Before it's here, it's on the Bloomberg Terminal
LEARN MORE
By Robert Langreth
June 20, 2024 at 10:04 AM EDT
Updated on
June 20, 2024 at 12:12 PM EDT
Save

Gilead Sciences Inc.'s experimental twice-yearly shot prevented 100%
of HIV cases in women and adolescent girls in Africa, the first
successful big trial of what's hoped to become a powerful new drug
regimen for fending off the virus.

Gilead hopes its new long-acting shot lenacapavir will provide an
easier-to-use option compared to other HIV prevention drugs that are
either daily pills or must be injected every two months. The two
yearly injections could be done at regularly scheduled doctor visits,
making it easy for people to get.

 
Have a confidential tip for our reporters? Get in Touch
 
Before it's here, it's on the Bloomberg Terminal
LEARN MORE
 
HomeBTV+Market DataOpinionAudioOriginalsMagazineEvents
News
MarketsEconomicsTechnologyPoliticsGreenCryptoAI
Work & Life
WealthPursuitsBusinessweekCityLabEqualityPursuitsWork Shift
Market Data
StocksCommoditiesRates & BondsCurrenciesFuturesSectorsEconomic
Calendar
Explore
NewslettersExplainersThe Big TakeGraphicsSubmit a TipAbout Us
Terms of ServiceDo Not Sell or Share My Personal Information
TrademarksPrivacy Policy
CareersMade in NYCAdvertise
Ad Choices
Help(c)2024 Bloomberg L.P. All Rights Reserved.